To OTC Journal Members:

Attention Contrarians: Biotech Alert!!!!!!! Biotech stocks were warm to red hot in the early part of the year. The IBB- the ETF for trading biotechs, made a multi year high in early March.

However, Americans now have a new national pastime in replacement of baseball: watching gasoline prices and other commodities go through the roof. Ever since oil prices spiked above the $70 thanks to nuclear saber rattling from Iran, oil has been on a tear, dragging other commodities like gold along with it.

You can almost watch the money pour out of formerly strong biotechs into energy and commodity related stocks. 

In my view the perfect time has arrived to begin accumulating microcap biotechs again. When the market turns its attention back to biotech, which is America's most vital progressive technology industry, biotechs will fly again. Heard anything about stem cells, cancer cures, bird flu, or aids recently? No- Time to buy.

Over the past 52 weeks two biotechs have been very good to OTC Journal members: 1. Callisto (AMEX: KAL)- $1.03 to $1.60, and 2. XNOM (OTC BB: XNOM)- last year- $1.80 to $4. 

Sticking with our principle of buying smart by identifying low risk entry points, check out the IBB-this is the biotech ETF. It is on a perfect 61.8% retracement right now. I am looking for a rebound in this group to start soon. The only question is when. For those who really like to speculate, a few carefully chosen call options in IBB might be a great way to participate in a rebound in the sector. It only takes one catalytic event. The chart you are looking at is a weekly chart, so think in terms of weeks, not days.

If you want to revisit a former major win for OTC Journal subscribers, one company with very exciting technology, trading in a very attractive range for accumulation, is XNOM- those who were around last year in June should recall I suggested locking in your profits at $4. Nearly a year later they have made a lot of progress on the technology front, and it is time to revisit this situation:
 

Xenomics (OTC BB: XNOM): Targets Infectious Conditions

Here's a chart of XNOM- as measured from the point last June when I suggested taking profits on the stock. The first thing of note- on a weekly chart the stock is at or near it's low- translation- very low risk entry point.

It the stock starts behaving like it did last year at this time look for the rebound to hit it's first level of resistance at $2.80- if it breaks through $2.80 the next level to look at would be $3.53. Last year it took flight over a several week period.

So, what has the company been up to in the last year? They have been developing a battery of different tests off their patented and proprietary transrenal DNA technology- technology that came out of the work done in Russia associated with radiation poisoning and Chernobyl. If you want a more detailed look at the overview, read our original presentation by clicking here. 

The technology represents an entire platform of tests that can be performed using urine instead of blood. It is based on the concept that DNA passes through transrenally- through the kidneys, and can be detected. 

Most recently, XNOM has experienced breakthroughs in the detection of a wide range of "Infectious Conditions". The most current test results coming out of their collaboration with the University of Bologna in Italy suggests their test can detect the H. pylori bacteria. This bacteria causes between 80% to 90% of duodenal and gastric ulcers.

According to the press release, the only current test for this bacteria is a surgical stomach biopsy or an antigen blood test.

Last year at this time the market became fascinated with XNOM's proprietary transrenal dna technology. Is it time for Deja Vu all over again? More applications are coming out of this company. We're at a very low risk entry point, lots of upside, and an industry group the market has temporarily decided to ignore. Time to own it.

Here is the complete text of this morning's press release for your review:
 

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketBtye LLC has been paid a fee of $30,000 and 100,000 warrants with an exercise price of $2.95, convertible into free trading shares, by Xenomics for coverage of the company.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $190,0000 in the Longview Fund (“the Longview Limited Partnership”), both limited partnerships in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership or the Longview Fund.  The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors.  Dutchess Advisors and Longview periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter.  Dutchess Advisors or Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors or Longview owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies. 

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 3525 Del Mar Heights Rd #334, San Diego, CA 92130.